Introduction {#s1}
============

Gastric cancer (GC) is the fourth most common malignant disease and the second most frequent cause of cancer-related deaths worldwide (Duo-Ji et al., [@B16]). Although the incidence of gastric cancer has declined in the past century, it is still one of the fatal diseases worldwide especially in developing countries (Abe et al., [@B1]). In 2008, up to 989,600 new gastric cancer cases and 738,000 related cases were reported (Song et al., [@B49]). Gastric cancer is often diagnosed at an advanced stage because there are no early signs or symptoms. Once the tumor invades over submucosa, it enters into advanced stage, according to Borrmann\' classification (Hu et al., [@B21]). Patients with advanced gastric cancer often suffer from weight loss, abdominal pain, nausea, or vomiting. So far, gastrectomy is still the only curative treatment for advanced gastric cancer (Duo-Ji et al., [@B16]). However, the results of gastrectomy are often unsatisfactory for patients\' high loco-regional recurrence rate (Duo-Ji et al., [@B16]) and poor survival rate (Desiderio et al., [@B13]). Most patients with gastric cancer still tend to relapse even in developed regions, and the 5-year overall survival rate stays nearly 40%. To offset the disadvantages of surgery alone, many explorations have been made to find out effective adjuvant therapies, including CT, RT, and CRT.

Radiotherapy (RT) plays an important role in clinic as one of the optional adjuvant treatments for patients with advanced gastric cancer. Radiation can interfere with the growth cycle of cells by damaging DNA replication and lead cancer cells to death. Although promising results on loco-regional recurrence control have been reported, there are many inevitable adverse effects alongside the use of RT due to surgical complications and patient discomfort. No definitive conclusion has been drawn on its effect of survival time (Abe et al., [@B1]; Calvo et al., [@B8]). Adjuvant chemotherapy (CT) is another option for gastric cancer patients after surgery and has been investigated on its potential to reduce the recurrence rate and increase the survival rate (Lim et al., [@B29]). In spite of the fact that postoperative CT can yield better survival results than surgery alone as indicated in some prior meta-analysis (Hermans et al., [@B20]; Panzini et al., [@B41]; Norman et al., [@B40]), several trials still present no statistical difference between postoperative CT and surgery regarding the comparison of OS and PFS (Kulig et al., [@B26]). The effectiveness of postoperative CT still remains unclear.

To improve the therapeutic efficacy of CT, chemoradiotherapy (CRT) was combined with CT and RT as a more comprehensive therapy (Smalley et al., [@B48]) and has shown its significant clinical benefit (Bamias et al., [@B4]). It was reported that postoperative CRT could significantly improve overall survival (OS) and relapse-free survival compared with surgery alone (Yu et al., [@B53]). In another trial, one-year, two-year, and three-year OS (1-OS, 2-OS, and 3-OS) rates as well as disease-free survival rate were significantly improved with adjuvant CRT (MacDonald et al., [@B32]). However, because of the use of radiation, CRT is also associated with high toxicity (Bamias et al., [@B4]).

Till now, a great amount of pair-wise meta-analysis has been conducted to compare either two of the three postoperative adjuvant therapies (CT, RT, CRT), trying to find out the most effective treatment with respect to survivaloutcomes. However, the results of those existing studies seem to be inconsistent. For instance, Soon et al. suggested that postoperative CRT significantly improved OS compared with CT (Soon et al., [@B50]) while Min et al. and Huang et al. found that there was no significant difference in terms of OS between CRT and CT (Huang et al., [@B22]; Min et al., [@B33]). Moreover, a great amount of pair-wise meta-analyses have been conducted to compare either two of the three postoperative adjuvant therapies (CT, RT, and CRT). But the results of comparison among all three therapies have not been integrally evaluated and no explicit conclusion among the relative efficacy of RT, CT, and CRT has been reached. In addition, conventional meta-analysis can only utilize direct evidence while NMA combines both direct and indirect evidence based on clinical trials and is believed to be of high reference value for clinical practice. In the lacking of direct head-to-head evidence between two therapies, NMA can be conducted if both of them have been compared to a same comparator. That is, an indirect estimate of the treatment A over B can be obtained by comparing trials of A vs. C and B vs. C. The estimate of treatment effect obtained from such an analysis is referred to as "indirect evidence". By NMA we can analysis the effect of more than two kinds of treatments even in the absence of direct head-to-head evidence between two treatments. Thus we extracted all available data to conduct the first NMA comparing these three popular adjuvant therapies which is of great clinical importance. By this means, the effect of the three therapies on prolonging the survival time of patients could be comprehensively explored and recommendations regarding the optimal treatment could be derived from copious trials.

Materials and methods {#s2}
=====================

Search strategy
---------------

Embase and PubMed were searched for all eligible RCTs. There was no limitation on the date of publication or the date of trials. Key terms used to select eligible studies included "gastric cancer," "surgery," "gastrectomy," "chemotherapy," "radiotherapy," "chemoradiotherapy," and "randomized controlled trials."

Selection criteria
------------------

In general, one study would be adopted if it satisfied all the following criteria: (1) all the patients were diagnosed with advanced gastric cancer (TNM classification of malignant tumors, 8th edition, 2016; Brierley, [@B7]); (2) all the treatments were postoperative; (3) the endpoints included either OS or PFS. Studies that belong to any one of categories below would be excluded: (1) studies without enough information for network analysis; (2) duplicate studies; (3) expert opinions, editorials, letters, case reviews, and reports.

Outcome measurements and data extraction
----------------------------------------

1-, 2-, 3-, and 5-yrs OS and PFS would be included as outcomes in this NMA. Although adverse events were reported in some of these studies, they would not be included in this NMA due to the missing data in over 75% of included studies. Two investigators participated in the data extraction process independently. Discrepancies were resolved with the intervention of a third investigator who acted as an arbitrator. For each study, basic information including first author, year of publication, country/region, follow-up, group size, completed size, population for different TNM-stage, median age, gender ratio, and treatment was also extracted.

Statistical analysis
--------------------

In order to evaluate the relative effectiveness of the three treatments, Bayesian NMA was adopted to integrate the comparison of network. Statistical analysis of HRs with 95% credible interval (95%CrIs) of OS and PFS, which were used to compare the efficacy of different treatments, was conducted by R software (Version 3.2.5). Considering the included studies might differ in population characteristics and the implementation methods of treatments, there would be different effect sizes among different studies. Hence we allowed true effects vary among studies, which rendered the random effects model to be applied in this NMA. The results of our analysis were presented by forest plots. The consistency analysis was exhibited in heat plot, in which the colors reflected the change in inconsistency when detracting one pair of direct comparison show in column. The warm color indicated an increase in consistency cold color illustrated an decrease. In addition, the *P*-score approach was utilized to rank the efficacy of therapies, with higher scores indicating better effectiveness of prolonging survival time. Based on the point estimates and standard errors of the frequentist network meta-analysis estimates under normality assumption, *P*-scores can be computed as unilateral *p*-values in order to measure the mean probability that one regimen is better than the others (Rücker and Schwarzer, [@B44]).

Furthermore, the Jadad scale (Table [S1](#SM3){ref-type="supplementary-material"}) was also used to independently assess the quality of the study included in our network meta-analysis.

Results {#s3}
=======

Literature search
-----------------

After researching, 4,359 studies were retrieved from the electronic database in total, among which 1,748 studies came from PubMed and 2,611 studies were from Embase. None of unpublished studies were identified. After reviewing title and abstract, 1,875 duplicates were removed and 2449 studies were excluded for the lack of sufficient information such as insufficient data and network connections or being found irrelevant in outcomes or contents (Figure [S1](#SM1){ref-type="supplementary-material"}). Finally, 35 randomized controlled trials (RCTs) published from 1982 to 2015 were adopted in this NMA to conduct a comprehensive comparison among the three postoperative therapies (Douglass and Stablein, [@B15]; Schlag et al., [@B46]; Moertel et al., [@B34]; Nakajima et al., [@B36], [@B35]; Engstrom et al., [@B17]; Bonfanti, [@B5]; Jakesz et al., [@B23]; Coombes et al., [@B10]; Krook et al., [@B25]; Grau et al., [@B18]; Hallissey et al., [@B19]; Lise et al., [@B30]; Macdonald et al., [@B31]; Neri et al., [@B38]; Tsavaris et al., [@B52]; Cirera et al., [@B9]; Bajetta et al., [@B3]; Skoropad et al., [@B47]; Nashimoto et al., [@B37]; Popiela et al., [@B43]; Bouché et al., [@B6]; Nitti et al., [@B39]; De Vita et al., [@B12]; Sakuramoto et al., [@B45]; Di Costanzo et al., [@B14]; Stahl et al., [@B51]; Bamias et al., [@B4]; Kulig et al., [@B26]; Kwon et al., [@B27]; Kim et al., [@B24]; Smalley et al., [@B48]; Yu et al., [@B53]; Zhu et al., [@B56]; Park et al., [@B42]).

Characteristics and network of included studies
-----------------------------------------------

The baseline characteristics of each study were presented in Table [1](#T1){ref-type="table"}. As shown in Figure [1](#F1){ref-type="fig"}, a total of 8,973 patients from various countries or regions were included, among which 980 patients received CRT, 3,934 patients received CT, 471 patients received RT, and 3,588 patients received no adjunctive therapy after surgery. The width of each edge is proportional to the number of RCTs comparing each pair of treatments while the size of each treatment node is proportional to the number of randomized participants (sample size). For the two types of outcome, 15 studies only reported OS and 2 studies only included PFS. In addition, 17 studies included both OS and PFS. The majority of the eligible studies were two-arm trials while one of them was three-arm trials. There are 5,103 patients in stage III/IV, indicating that most patients are in an advanced stage. 4554 patients received D2 lymph node dissection, which also account for a major part of all patients. Male subjects accounted for over 60% of all participants in most of the included trails.

###### 

Main characteristics of included studies.

  **References, country**                **Design**   **Follow-up (Months)**   **Type**   **Size/Completed size**   **Men (%)**   **Age**         **Stage**[^\*^](#TN1){ref-type="table-fn"}   **Regimen**   **Outcomes**                     
  -------------------------------------- ------------ ------------------------ ---------- ------------------------- ------------- --------------- -------------------------------------------- ------------- -------------------------------- --------
  (Park et al., [@B42]), South Korea     RCT          84                       CT         228/172                   67.00         56 (22--77)     50/86                                        65/27         Cap and Cis                      OS
                                                                               CRT        230/188                   62.00         56 (28--76)     49/84                                        71/26         45 Gy RT+ Cap and Cis            
  (Zhu et al., [@B56]), China            RCT          60                       CRT        205/186                   72.90         56 (38--73)     15/30                                        96/24         5-FU and L+45 Gy RT              OS
                                                                               CT         175/165                   76.40         56 (42--75)     20/36                                        103/27        5-FU and L                       
  (Smalley et al., [@B48]), USA          RCT          123.6                    CRT        282/182                   --            --              175                                          346/38        5-FU and L+45 Gy RT              OS&PFS
                                                                               S          277/266                   --            --                                                                         --                               
  (Kim et al., [@B24]), Korea            RCT          117                      CRT        46/40                     73.90         --              0/0                                          34/12         5-FU and L+45Gy RT               PFS
                                                                               CT         44/41                     56.80         --              0/0                                          33/11         5-FU and L                       
  (Yu et al., [@B53]), China             --           36                       CRT        34/30                     39.29         56              0/3                                          22/9          5-FU and TF +45Gy RT             OS
                                                                               CT         34/34                     36.84         57              0/4                                          20/10         5-FU and TF                      
  (Kwon et al., [@B27]), Korea           RCT          93                       CRT        31/23                     67.70         --              0/0                                          24/7          5-FU and Cis + 45Gy RT and Cap   OS&PFS
                                                                               CT         30/22                     76.70         --              0/0                                          27/3          5-FU and Cis                     OS
  (Kulig et al., [@B26]), Poland         RCT          65                       CT         141/101                   71.00         61 (58--67)     20/24                                        54/43         Et, A and Cis                    
                                                                               S          154/154                   72.00         64 (61--66)     19/32                                        44/49         --                               
  (Bamias et al., [@B4]), Greece         RCT          53.7                     CRT        72/49                     67.00         63 (32--75)     0/18                                         47/7          D and Pl + 45Gy RT               OS&PFS
                                                                               CT         71/61                     73.00         62 (41--79)     3/19                                         38/10         D and Pl                         
  (Stahl et al., [@B51]), German         RCT          65                       CRT        60/45                     90.00         61              0/0                                          55/5          Cis, 5-FU, L + 15-17Gy RT        OS&PFS
                                                                               CT         59/39                     92.00         56              0/0                                          54/5          Cis, 5-FU, L                     
  (Di Costanzo et al., [@B14]), Italy    RCT          73                       CT         130/75                    61.00         59 (32--73)     19/32                                        71/7          Cis, Ep, L and 5-FU              OS&PFS
                                                                               S          128/--                    61.00         59 (18--71)     12/36                                        75/3          --                               
  (Sakuramoto et al., [@B45]), Japan     RCT          60                       CT         529/--                    69.40         63 (27--81)     1/264                                        224/40        S-1                              
                                                                               S          530/--                    69.60         63 (33--80)     0/282                                        213/35        --                               
  (De Vita et al., [@B12]), Italy        RCT          60                       CT         112/92                    59.00         63 (39--70)     1/38                                         74/0          Ep, L, 5-FU and Et               OS
                                                                               S          113/-                     58.00         62 (41--70)     3/35                                         75/0          --                               
  (Nitti et al., [@B39]), Belgium        RCT          108                      CT         103/76                    61.00         56 (29--70)     14/23                                        61/0          5-FU, A and MTX with L           OS&PFS
                                                                               S          103/--                    62.00         57 (29--70)     12/27                                        64/0          --                               
  (Bouché et al., [@B6]), France         RCT          98                       CT         127/79                    73.20         60 (32--82)     0/43                                         65/19         5-FU and Cis                     OS&PFS
                                                                               S          133/--                    69.60         62 (31--83)     0/48                                         72/10                                          
  (Popiela et al., [@B43]), Poland       RCT          120                      CT         53/--                     81.13         58              0/0                                          38/15         5-FU, A, M                       OS
                                                                               S          52/--                     59.62         60              0/0                                          42/10         --                               
  (Nashimoto et al., [@B37]), Japan      RCT          84                       CT         128/80                    73.20         58.4 (33--75)   53/67                                        7/0           M, 5-FU and Cy + oral FU         OS&PFS
                                                                               S          123/123                   61.80         57.5 (25--75)   53/61                                        9/0           --                               
  (Skoropad et al., [@B47]), Russia      RCT          240                      RT         51/51                     68.63         55 (25--75)     16/16                                        15/4          20Gy RT                          OS
                                                                               S          51/51                     76.47         54 (36--71)     11/17                                        18/4          --                               
  (Bajetta et al., [@B3]), Italy         RCT          66                       CT         135/117                   60.00         57 (23--70)     65                                           70            Et, A and Cis + 5-FU and L       OS&PFS
                                                                               S          136/128                   68.38         57 (31--70)     63                                           73            --                               
  (Nakajima et al., [@B35]), Japan       RCT          72                       CT         288/275                   60.40         --              97/156                                       32/0          M, 5-FU + uracil and tegafur     OS
                                                                               S          285/281                   66.30         --              91/167                                       30/0          --                               
  (Cirera et al., [@B9]), Spain          RCT          76                       CT         76/72                     68.00         --              1/5                                          17/53         M+ oral tegafur                  OS&PFS
                                                                               S          72/72                     58.00         --              2/6                                          22/42         --                               
  (Tsavaris et al., [@B52]), Greece      RCT          72                       CT         42/--                     76.19         53 (41--65)     0/19                                         23/0          5-FU, Ep and M                   OS
                                                                               S          42/--                     59.52         57 (35--66)     0/25                                         17/0          --                               
  (Neri et al., [@B38]), Italy           RCT          36                       CT         48/43                     68.75         61 (31--70)     0/4                                          24/20         Ep, L and 5-FU                   OS
                                                                               S          55/--                     70.91         63 (35--73)     1/5                                          27/22         --                               
  (Macdonald et al., [@B31]), USA        RCT          180                      CT         93/--                     63.00         59 (27--75)     17/40                                        36/0          5-FU, A, M                       OS&PFS
                                                                               S          100/--                    64.00         60 (18--76)     22/42                                        36/0          --                               
  (Lise et al., [@B30]), Belgium         RCT          144                      CT         155/75                    61.00         --              5/63                                         76/9          5-FU, A, M                       OS
                                                                               S          159/--                    68.00         --              7/63                                         68/20         --                               
  (Hallissey et al., [@B19]), UK         RCT          60                       CT         138/58                    71.01         63 (58--68)     0/23                                         71/44         5-FU, A, M                       OS
                                                                               RT         153/102                   64.71         65 (55--69)     0/21                                         79/53         45Gy RT                          
                                                                               S          145/145                   73.10         63 (57--69)     0/27                                         71/47         --                               
  (Grau et al., [@B18]), Spain           RCT          144                      CT         68/--                     64.71         56 (34--70)     0/31                                         37/0          M                                OS
                                                                               S          66/--                     66.67         57 (30--70)     0/30                                         36/0          --                               
  (Krook et al., [@B25]), USA            RCT          60                       CT         61/55                     77.00         63 (33--77)     19                                           42            5-FU, A                          OS&PFS
                                                                               S          64/--                     80.00         62 (38--78)     21                                           43            --                               
  (Coombes et al., [@B10]), USA          RCT          60                       CT         133/--                    --            --              0/39                                         92/0          5-FU, A, M                       OS&PFS
                                                                               S          148/--                    --            --              0/41                                         107/0         --                               
  (Jakesz et al., [@B23]), Austra        RCT          60                       CT         53/--                     --            --              0/25                                         37/25         5-FU, M and Cy                   OS
                                                                               S          34/--                     --            --                                                                         --                               
  (Bonfanti, [@B5]), Italy               RCT          84                       CT         75/67                     60.00         --              11/26                                        38            5-FU, Me-CCNU                    OS
                                                                               S          69/69                     63.77         --              17/23                                        29            --                               
  (Engstrom et al., [@B17]), USA         RCT          64                       CT         91/--                     62.64         --              25                                           66            5-FU, Me-CCNU                    OS&PFS
                                                                               S          89/--                     70.79         --              23                                           65            --                               
  (Nakajima et al., [@B36]), Japan       RCT          70                       CT         154/--                    47.40         --              12/21                                        59/8          M, 5-FU, Cy, F'                  OS
                                                                               S          153/--                    50.98         --              8/30                                         47/15         --                               
  (Moertel et al., [@B34]), USA          RCT          96                       CRT        39/--                     74.36         --              0/5                                          12/22         5-FU + RT                        PFS
                                                                               S          23/--                     73.91         56 (41--67)     0/2                                          8/13          --                               
  (Schlag et al., [@B46]), Germany       RCT          36                       CT         49/--                     61.22         59.8            --                                           --            5-FU, BCNU                       OS&PFS
                                                                               S          54/--                     61.11         57.6            --                                           --            --                               
  (Douglass and Stablein, [@B15]), USA   RCT          60                       CT         71/--                     70.42         --              --                                           --            5-FU, Me-CCNU                    OS&PFS
                                                                               S          71/--                     70.42         --              --                                           --            --                               

*CT, Chemotherapy; RT, Radiotherapy; CRT, Chemoradiotherapy; S, Surgery; Cap, capecitabine; Cis, cisplatin; FU, fluorouraci; 5-FU, 5-fluorouraci; L, leucovorin; TF, tetrahydrofolic acid; Et, etoposide; A, Adriamycin; D, docetaxel; Pl, platinum; Ep, epirubicin; S-1, Tegafur + 5-FU + Potassium oxonate; MTX, methotrexate; Cy, cytarabine; Me-CCNU, semustine; F', ftorafur; BCNU, carmusine; OS,overall survival; PFS, progression-free survival*.

*The stage of cancer is categorized by TNM classification of malignant tumors, 8th edition*.

![Network structure. The network plots show direct comparison of different treatments, with node size corresponding to the sample size. The number of included studies for specific direct comparison decides the thickness of solid lines. CT, Chemotherapy; RT, Radiotherapy; CRT, Chemoradiotherapy; S, Surgery.](fphar-09-00929-g0001){#F1}

Comparison of treatments
------------------------

This NMA was conducted to reveal the relative efficacy on prolonging the survival time of patients. As shown in Figure [2](#F2){ref-type="fig"}, CRT performed better than both surgery alone and CT in terms of 1-OS (S: HR = 0.64, 95%CrI: 0.47--0.88; CT: HR = 0.72, 95%CrI: 0.54--0.96). With respect to 2-OS, CRT also yielded better outcome than all other treatments (S: HR = 0.66, 95%CrI: 0.53--0.82; CT: HR = 0.74, 95%CrI: 0.61--0.90; RT: HR = 0.74, 95%CrI: 0.61--0.91). The results of 3-OS and 5-OS shown in Figure [3](#F3){ref-type="fig"} were similar to the previous results. In terms of 3-OS, CRT and CT revealed better efficacy compared with surgery alone (CRT: HR = 0.78, 95%CrI: 0.67--0.91; CT: HR = 0.88, 95%CrI: 0.80--0.97). They also exhibited a longer survival time when compared with RT (CRT: HR = 0.75, 95%CrI: 0.66--0.87; CT: HR = 0.85, 95%CrI: 0.73--0.99). The similar results existed when comparing 5-OS, with CRT and CT superior to both surgery alone (CRT: HR = 0.80, 95%CrI: 0.69--0.92; CT: HR = 0.87, 95%CrI: 0.80--0.95) and RT (CRT: HR = 0.74, 95%CrI: 0.65--0.84; CT: HR = 0.81, 95%CrI: 0.70--0.93).

![Forest plots for 1- and 2-yr OS. Hazard ratios (HRs) with 95% credible interval (CrIs) indicate the relative efficacy. CT, Chemotherapy; RT, Radiotherapy; CRT, Chemoradiotherapy; S, Surgery; OS, Overall survival.](fphar-09-00929-g0002){#F2}

![Forest plots for 3- and 5-yr OS. Hazard ratios (HRs) with 95% credible interval (CrIs) indicate the relative efficacy. CT, Chemotherapy; RT, Radiotherapy; CRT, Chemoradiotherapy; S, Surgery; OS, Overall survival.](fphar-09-00929-g0003){#F3}

According to the comparison of PFS presented in Figures [4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}, CRT was significantly superior to surgery alone (1-PFS: HR = 0.55, 95%CrI: 0.39--0.80; 2-PFS: HR = 0.58, 95%CrI: 0.45--0.76; 3-PFS: HR = 0.69, 95%CrI: 0.56--0.86; 5-PFS: HR = 0.70, 95%CrI: 0.57--0.85). Moreover, CT showed a significant advantage over surgery as well (1-PFS: HR = 0.64, 95%CrI: 0.50--0.82; 2-PFS: HR = 0.80, 95%CrI: 0.68--0.94; 3-PFS: HR = 0.82, 95%CrI: 0.73--0.93; 5-PFS: HR = 0.83, 95%CrI: 0.75--0.92). Meanwhile there was statistical difference between CRT and CT in terms of 2-PFS (HR = 0.73, 95%CrI: 0.59--0.90). CRT also yielded better outcomes than RT with respect to PFS (2-PFS: HR = 0.76, 95%CrI: 0.59--0.97; 3-PFS: HR = 0.75, 95%CrI: 0.65--0.87; 5-PFS: HR = 0.76, 95%CrI: 0.66--0.88).

![Forest plots for 1- and 2-yr PFS. Hazard ratios (HRs) with 95% credible interval (CrIs) indicate the relative efficacy. CT, Chemotherapy; RT, Radiotherapy; CRT, Chemoradiotherapy; S, Surgery; PFS, Progression-free survival.](fphar-09-00929-g0004){#F4}

![Forest plots for 3- and 5-yr PFS. Hazard ratios (HRs) with 95% credible interval (CrIs) indicate the relative efficacy. CT, Chemotherapy; RT, Radiotherapy; CRT, Chemoradiotherapy; S, Surgery; PFS, Progression-free survival.](fphar-09-00929-g0005){#F5}

Ranking of treatments
---------------------

All three adjuvant therapies and surgery alone were sequenced according to *P*-score ranking calculated by software R (version 3.2.5), with the result of which presented in Table [2](#T2){ref-type="table"}. According to the *P*-score ranking result, CRT ranked first in all survival terms, which indicated it being the best regimen regarding efficacy of prolonging survival time and progression-free period of patients. RT ranked higher than CT in terms of 1-OS, 1-PFS, and 2-PFS, while the results reversed with respect to 2-OS, 3-OS, 5-OS, 3-PFS, and 5-PFS. Surgery without adjuvant therapies ranked last in all outcome measurements as expected except in 3-OS and 5-OS whereas RT ranked lowest with regard to 3-OS and 5-OS.

###### 

*P*-score ranking.

  **Treatment**   **1-OS**   **2-OS**   **3-OS**   **5-OS**   **1-PFS**   **2-PFS**   **3-PFS**   **5-PFS**
  --------------- ---------- ---------- ---------- ---------- ----------- ----------- ----------- -----------
  CRT             0.905      0.999      0.980      0.961      0.888       0.995       0.989       0.991
  CT              0.322      0.479      0.678      0.705      0.540       0.473       0.618       0.615
  RT              0.715      0.452      0.115      0.040      0.558       0.505       0.304       0.310
  S               0.058      0.070      0.228      0.295      0.013       0.028       0.089       0.084

*CT, Chemotherapy; RT, Radiotherapy; CRT, Chemoradiotherapy; S, Surgery; OS, Overall survival; PFS, Progression-free survival*.

Consistency test and publication bias
-------------------------------------

The included trials demonstrated to be of high quality according to Jadad scale we performed in Table [S1](#SM3){ref-type="supplementary-material"}. There is no evidence of inconsistency among most comparisons as shown in heat plots (Figures [6](#F6){ref-type="fig"}, [7](#F7){ref-type="fig"}), which contributed to the reliability of this NMA. However, the comparison in 1-OS should be noticed due to its high possibility of inconsistency. In terms of publication bias, the results of Begg\'s test (Figure [S2](#SM2){ref-type="supplementary-material"}) shows that basically no small study effects exist in our NMA.

![Heat plots for 1- and 2-yr OS, and 1- and 2-yr PFS The size of the gray squares indicates the contribution of the direct evidence (shown in the column) to the network evidence (shown in the row). The colors are associated with the change in inconsistency between direct and indirect evidence (shown in the row). Cold colors indicate a decrease of inconsistency and warm colors indicate an increase. CT, Chemotherapy; RT, Radiotherapy; CRT, Chemoradiotherapy; S, Surgery; OS, Overall survival; PFS, Progression-free survival.](fphar-09-00929-g0006){#F6}

![Heat plots for 3- and 5-yr OS, and 3- and 5-yr PFS The size of the gray squares indicates the contribution of the direct evidence (shown in the column) to the network evidence (shown in the row). The colors are associated with the change in inconsistency between direct and indirect evidence (shown in the row). Cold colors indicate a decrease of inconsistency and warm colors indicate an increase. CT, Chemotherapy; RT, Radiotherapy; CRT, Chemoradiotherapy; S, Surgery; OS, Overall survival; PFS, Progression-free survival.](fphar-09-00929-g0007){#F7}

Discussion {#s4}
==========

A total of 35 RCTs with 8,973 patients were included in our NMA. As for efficacy outcomes, which included OS and PFS of 1, 2, 3, and 5 years, all revealed that the excellent performance of CRT as the best of three adjuvant therapies. Meanwhile, *P*-score ranking results also displayed that CRT was the optimal regimen. The optimal status of CRT has been confirmed by prior meta-analyses as mentioned ahead. For instance, papers by Zhou et al., Soon et al., and Dai et al. all suggested a survival benefit of CRT over other adjuvant therapies (Soon et al., [@B50]; Dai et al., [@B11]; Zhou et al., [@B54]). Additionally, RT and CT were two alternative options following CRT since RT performed well in short-term survival while CT could improve the long-term survival.

In this NMA, the exclusion criteria along with the amount of studies with different years of publication guaranteed the reliability of research sources. Although there existed some discrepancy regarding the background of patients and different chemicals utilized in the treatments that may lead to inter-study heterogeneity, we tried to reduce it by restricting the study design and outcome types. Yet subgroup analysis turned out to be impractical for us due to the fact that a large portion of the included studies did not report surgery types while the great majority of those reported surgery types contained not only one kind of surgery. Thus further study could be carried out on the basis of more specific subgroup analysis.

A total of eight outcomes were covered and all the outcomes were measured by HRs with 95%CrIs. According to the forest plots, all the treatments except RT performed better than surgery alone in most outcomes including 1-OS, 3-OS, 5-OS, 1-PFS, 2-PFS, 3-PFS, and 5-PFS, which indicated the absolute efficacy of CT and CRT. However, there was no statistical significance between RT and surgery in any outcomes meanwhile the *P*-score ranking revealed that RT was worse than surgery in long-term measurements. The undesirable performance of RT may be caused by its adverse effects or the insufficiency of trials conducting RT in this NMA. In the meta-analysis carried out by Li et al. ([@B28]), it was found that, in patients with resectable gastric cancer, preoperative RT could improve OS while postoperative RT couldn\'t. The efficacy variation between preoperative and postoperative RT treatments indicated that further study should be conducted to adequately investigate the value of RT. On the other hand, it turned out that CRT was the most effective treatment because of its great potential to prolong survival time of patients with advanced gastric cancer. CT and RT were alternative options with the former one improving long-term such as 3-year survival and 5-year survival while the latter doing well in short-term survival, such as 1- and 2-year survival. Actually, the effect of CT has been confirmed in previous studies. Notably, the curative effect varies with the corresponding chemotherapeutics. For example, a study conducted by (Di Costanzo et al., [@B14]; Zhu X. et al., [@B57]) reported that postoperative chemotherapy based on fluorouracil had little effect on improving long-term survival rate of patients (5-OS: HR = 1.08, 95%CrI = 0.68--1.72) compared with surgery alone, yet another study conducted by (Sakuramoto et al., [@B45]; Zhu L. et al., [@B55]) suggested that the use of S-1 in postoperative chemotherapy could significantly benefit long-term survival (5-OS: HR = 0.73, 95%CrI = 0.56--0.94). Different drug combinations may lead to diverse directions thus specific combinations of drugs used in postoperative chemotherapy should be further identified and evaluated. Meanwhile, the safety of different CT regimens is still not clear. Although some studies tried to figure out safety profile, there was still no conclusion (Zhu L. et al., [@B55]). In addition to CT, the performance of RT should also be further examined. First of all, the sample size of patients treated with RT is relatively small, indicating the insufficiency of evidence supporting NMA results of RT effect. Secondly, most included studies involving RT only demonstrated the comparison of RT and surgery alone, which to some extent made direct comparison between RT and CRT or CT inadequate. Moreover, the implementation of RT can cause a lot of adverse effects on patients, which may dilute its positive impact on survival (Badiani et al., [@B2]).

As for the tolerability of these therapies, according to current studies, CRT and CT was indicated to show no significant differences in terms of toxicity when treating gastric cancer patients (Li et al., [@B28]) while CRT has been proved to be well-tolerated after D2 resection (Zhu et al., [@B56]; Park et al., [@B42]). However, another study pointed out that approximately 17% patients stopped treatment because of toxicity when received CRT (Smalley et al., [@B48]), making it more complicated to draw the conclusion toward the safety of CRT and CT. Similar inconsistency existed regarding RT. It was believed having significant toxicity (Bamias et al., [@B4]) but was shown to be safe when treating patients (Skoropad et al., [@B47]).

Despite being conducted as scrupulously as possible, this NMA has several limitations.

Firstly, the characteristics of the included studies confined the quality of our analysis. For instance, the most obvious flaw is that the endpoint measuring the level of safety was not covered. In fact, toxicity is an important outcome of adjuvant therapies because patients tend to report adverse events and discomfort as the symptom of cancers after exposure to drugs or radiation. Some of the included studies did report adverse events, such as leucopenia, anemia, fatigue, and diarrhea. However, due to the absence of data in most trials (over 75%), adverse effects could not be assessed in this NMA, which is the reason why no analysis concerning safety was conducted. Besides, the tolerability to the therapies varies among various subpopulations. To be specific, old subjects might be more vulnerable; various races could response differently. Yet due to a lack of sufficient data on population characteristics, a stratified analysis was not conducted in our NMA.

Secondly, blinding methods were different among all included RCTs, which increased the heterogeneity of this study to some extent. However, since only a limited number of trials investigating RT were made, the reason of which may lie in its strong adverse effects, exclusion of this article may also lead to unreliable results. Similarly, the high intensity of inconsistency exists in the comparison of 1-OS between RT and other treatments. Also, the regimen of chemotherapy and the dose of radiotherapy or CRT are different in each study. This difference would have an impact on conclusions in this study, yet according to the final rank, CRT still had an obvious advantage over other treatments.

Thirdly, despite the fact that most included studies were conducted before 2012, the time span from 1982 to 2015 might still be excessive big to some extent. Such a time span might undermine the forwardness of our results. Also, other medical factors such as the development of treatments involved and therapeutic environment might have varied considerably since 1980s. The standards of gastrectomy plus lymphadenectomy in different time are variable. Thus the degree of heterogeneity of our NMA could be increased due to the wide time range.

In conclusion, CRT is the most recommended adjuvant therapy for people with advanced gastric cancer because of its advantage in prolonging long-term survival rate according to the NMA results. Whereas due to the absence of data concerning adverse events of this therapy, its safety assessment still remains unclear, which requires more studies recording adverse events for a more comprehensive analysis.
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